WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464345
CAS#: 1189922-23-3
Description: Triamterene-d5 is intended for use as an internal standard for the quantification of triamterene by GC- or LC-MS. Triamterene is an inhibitor of the epithelial sodium channel (ENaC; IC50 = 4.5 µM for the rat channel). In vivo, triamterene (0.5-32 mg/animal) enhances sodium secretion and decreases potassium secretion in adrenalectomized rats.2 Formulations containing triamterene have been used in the treatment of edema.
Hodoodo Cat#: H464345
Name: Triamterene-d5
CAS#: 1189922-23-3
Chemical Formula: C12H6D5N7
Exact Mass: 258.14
Molecular Weight: 258.300
Elemental Analysis: C, 55.80; H, 6.24; N, 37.96
Synonym: Triamterene-d5; Triamterene d5; 2,4,7-Triamino-6-phenylpteridine-d5;
IUPAC/Chemical Name: 6-(phenyl-d5)pteridine-2,4,7-triamine
InChi Key: FNYLWPVRPXGIIP-RALIUCGRSA-N
InChi Code: InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)/i1D,2D,3D,4D,5D
SMILES Code: NC1=NC(N)=NC2=C1N=C(C(N)=N2)C3=C(C([2H])=C(C([2H])=C3[2H])[2H])[2H]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 258.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Triamterene. 2021 Mar 17. PMID: 30000336.
2: Essigke D, Ilyaskin AV, Wörn M, Bohnert BN, Xiao M, Daniel C, Amann K, Birkenfeld AL, Szabo R, Bugge TH, Korbmacher C, Artunc F. Zymogen-locked mutant prostasin (Prss8) leads to incomplete proteolytic activation of the epithelial sodium channel (ENaC) and severely compromises triamterene tolerance in mice. Acta Physiol (Oxf). 2021 Mar 1:e13640. doi: 10.1111/apha.13640. Epub ahead of print. PMID: 33650216.
3: Hu LX, Wang D, Liu HL, Zhang QT, Sun DS, Zhang L, Chen X, Chang GL, Wang JG. A double-blind, placebo-controlled trial on the antihypertensive treatment effect of a quadruple single-pill combination. J Clin Hypertens (Greenwich). 2021 Feb 6. doi: 10.1111/jch.14207. Epub ahead of print. PMID: 33548084.
4: Donthi N, Chandrabhatla T, Genovese L, deFilippi C. Fast and furious: flecainide toxicity presenting as monomorphic ventricular tachycardia. BMJ Case Rep. 2020 Dec 13;13(12):e236932. doi: 10.1136/bcr-2020-236932. PMID: 33318242; PMCID: PMC7737056.
5: Maeda H, Shiobara R, Tanaka M, Kajinami A, Nakayama H. Effect of mechanochemical inclusion of triamterene into sulfobutylether-β-cyclodextrin and its improved dissolution behavior. Drug Dev Ind Pharm. 2020 Nov 13:1-25. doi: 10.1080/03639045.2020.1850759. Epub ahead of print. PMID: 33185132.
6: Onoda H, Inoue Y, Ezawa T, Murata I, Chantadee T, Limmatvapirat S, Oguchi T, Kanamoto I. Preparation and characterization of triamterene complex with ascorbic acid derivatives. Drug Dev Ind Pharm. 2020 Dec;46(12):2032-2040. doi: 10.1080/03639045.2020.1842439. Epub 2020 Nov 1. PMID: 33104388.
7: Aghsaeifard Z, Alizadeh R. Drug-induced interstitial nephritis as a result of sodium valproate and triamterene. Urol Case Rep. 2020 Jun 26;33:101329. doi: 10.1016/j.eucr.2020.101329. PMID: 33102031; PMCID: PMC7573849.
8: Niyazov R, Sharman T. Triamterene. 2020 Oct 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32491582.
9: Madhok J, Kloosterboer A, Venkatasubramanian C, Mihm FG. Catecholamine- induced cerebral vasospasm and multifocal infarctions in pheochromocytoma. Endocrinol Diabetes Metab Case Rep. 2020 Aug 20;2020:20-0078. doi: 10.1530/EDM-20-0078. Epub ahead of print. PMID: 32820130; PMCID: PMC7487175.
10: Inoue M, Nakai K, Mitsuiki K. Triamterene in lithium-induced nephrogenic diabetes insipidus: a case report. CEN Case Rep. 2021 Feb;10(1):64-68. doi: 10.1007/s13730-020-00517-2. Epub 2020 Aug 9. PMID: 32772236; PMCID: PMC7829309.
11: Stokes ME, Small JC, Vasciaveo A, Shimada K, Hirschhorn T, Califano A, Stockwell BR. Mesenchymal subtype neuroblastomas are addicted to TGF-βR2/HMGCR- driven protein geranylgeranylation. Sci Rep. 2020 Jul 1;10(1):10748. doi: 10.1038/s41598-020-67310-0. PMID: 32612149; PMCID: PMC7329873.
12: Drugs for hypertension. Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. PMID: 32555118.
13: Khan MS, Gao J, Chen X, Zhang M, Yang F, Du Y, Moe TS, Munir I, Xue J, Zhang X. The Endophytic Bacteria Bacillus velezensis Lle-9, Isolated from Lilium leucanthum, Harbors Antifungal Activity and Plant Growth-Promoting Effects. J Microbiol Biotechnol. 2020 May 28;30(5):668-680. doi: 10.4014/jmb.1910.10021. PMID: 32482932.
14: Hinrichs GR, Jensen BL, Svenningsen P. Mechanisms of sodium retention in nephrotic syndrome. Curr Opin Nephrol Hypertens. 2020 Mar;29(2):207-212. doi: 10.1097/MNH.0000000000000578. PMID: 31789848.
15: Pfisterer N, Stöllberger C, Finsterer J. Severe Acquired Hypokalemic Paralysis in a Bodybuilder After Self-Medication With Triamterene/Hydrochlorothiazide. Clin J Sport Med. 2020 Sep;30(5):e172-e174. doi: 10.1097/JSM.0000000000000763. PMID: 31770156.
16: Mills WD, Greenhaw RM, Wang JMP. A Medical Review of Fatal High-G U.S. Aerobatic Accidents. Aerosp Med Hum Perform. 2019 Nov 1;90(11):959-965. doi: 10.3357/AMHP.5445.2019. PMID: 31666158.
17: Enslow BT, Stockand JD, Berman JM. Liddle's syndrome mechanisms, diagnosis and management. Integr Blood Press Control. 2019 Sep 3;12:13-22. doi: 10.2147/IBPC.S188869. PMID: 31564964; PMCID: PMC6731958.
18: Zhu GH, Sun XP, Li J, Pi L, Tang HQ, Gao HQ, Cong HL, Qu P, Lu XZ, Zhang XJ, Zhao LS, Guo YF, Liu DX, Zhang LQ, Tang H, Hu YX, Fan L, Hua Q. No association between low-dose reserpine use and depression in older hypertensive patient: result of a multicenter, cross-sectional study. J Geriatr Cardiol. 2019 Aug;16(8):608-613. doi: 10.11909/j.issn.1671-5411.2019.08.001. PMID: 31555328; PMCID: PMC6748907.
19: Suresh K, Matzger AJ. Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metal-Organic Framework (MOF). Angew Chem Int Ed Engl. 2019 Nov 18;58(47):16790-16794. doi: 10.1002/anie.201907652. Epub 2019 Oct 11. PMID: 31550411.
20: Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick B, Montastruc JL. Breast cancer and spironolactone: an observational postmarketing study. Eur J Clin Pharmacol. 2019 Nov;75(11):1593-1598. doi: 10.1007/s00228-019-02740-y. Epub 2019 Aug 15. PMID: 31418056.
